Can we reach an “age of immunity”? Aditxt pushes FDA for Covid-19 antibody tests

Be the First to Comment Read

Can we reach an “age of immunity”? Aditxt pushes FDA for Covid-19 antibody tests

Aditxt has submitted more than one request to FDA for Emergency Use Authorization for AditxtScore™ for COVID-19 Tests. These tests are unique as they Measure the Quantity and Quality of Antibodies Against COVID-19 individuals have developed. It’s designed to identify Covid-19 and its Variants Including Omicron. Aditxt follows the guidelines imposed by the US FDA regarding timelines for laboratory-developed tests (“LDT”s), they have requested Emergency Use Authorization (“EUA”) by January 14 2022. 

Disclaimer

Speak your Mind

Ad
kalkine logo

GET A FREE STOCK REPORT

Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK